Pediatric Common Variable Immunodeficiency
- Author: C Lucy Park, MD; Chief Editor: Harumi Jyonouchi, MD more...
Common variable immunodeficiency (CVID), one of the most prevalent primary immunodeficiency diseases, is a heterogeneous group of immunologic disorders of unknown etiology. CVID is characterized by marked reduction in serum levels of immunoglobulin G (IgG) and immunoglobulin A (IgA), as well as reduced immunoglobulin M (IgM) in about half of cases.
Signs and symptoms
Clinical manifestations of CVID include the following:
Recurrent infections may include the following:
Pyogenic sinopulmonary tract infection, especially after puberty
In some cases, infections with unusual organisms (eg, Pneumocystis jiroveci, mycobacteria, various fungi)
Mycoplasma pneumoniae infections in the urinary tract, joints, and deep abscesses
Persistent diarrhea and malabsorption caused by Giardia lamblia
Severe and recurrent infections with herpes simplex
Unusual enteroviral infections with a chronic meningoencephalitis and a dermatomyositis-like illness; presenting symptoms are either acute or insidious, with signs of encephalitis, seizures, headache, sensory motor disturbances, and personality changes
Autoimmune conditions in patients with CVID are as follows:
Idiopathic thrombocytopenic purpura (ITP)
More rarely, autoimmune neutropenia
Other solid organ–specific autoimmune diseases (eg, pernicious anemia, thyroid diseases, vitiligo)
Systemic lupus erythematosus
Juvenile rheumatoid arthritis
Severe gastroenteropathy with severe malabsorption, nodular lymphoid hyperplasia, and chronic inflammatory bowel disease (eg, ulcerative colitis, Crohn disease)
Physical examination findings may include the following:
Generalized lymphadenopathy and splenomegaly
Failure to thrive in young children, secondary to frequent infection and increased energy expenditure
See Clinical Presentation for more detail.
The diagnosis of CVID is based on the following:
Defective functional antibody formation (eg, low IgG response to vaccination)
Decreased (not absent) serum immunoglobulin (Ig)G and IgA levels (usually)
Decreased serum IgM level (generally, but not invariably)
Exclusion of other known causes of antibody deficiency
See Workup for more detail.
A major component of medical care is anti-infective and prevention of further infectious episodes by regular infusion of human immunoglobulin and antimicrobial therapy. Patients with autoimmune manifestations may require immunosuppressive therapy.
Immunoglobulin replacement is intravenously administered on a regular basis, as follows:
Tailor dose and frequency to the Ig trough levels and to clinical symptoms
Measure serum IgG level before each infusion, and accordingly adjust the dose of IVIG
Maintain trough serum IgG concentrations at 400-500 mg/dL in adults
For most patients, a dose of 400-600 mg/kg every 3-4 weeks suffices to reduce the frequency of infection
Some patients with chronic lung disease require up to 600-800 mg/kg per month
Once established on a regular regimen, IVIG can be administered at home
Subcutaneous infusion of Ig (SCIG) is an alternative method for patients with difficult venous access or for those who experience serious side effects from IVIG.
Anti-infective treatment is as follows:
Infections should be treated early with full doses of antimicrobial agents
Whenever possible, narrow-spectrum drugs should be used on the basis of microbial sensitivity testing
Prophylactic antibiotics should be avoided
Antiviral agents may be useful in some patients with persistent or severe viral infections
Some patients with a severe autoimmune process may require immunosuppressive therapy with one of the following:
Anti-CD20 monoclonal antibody (rituximab)
Anti-TNF monoclonal antibody (infliximab)
The common immunologic defect in patients with common variable immunodeficiency is defective antibody formation. As is expected in a heterogeneous group of diseases, many different immune system defects have been reported in this group of patients.
The basic and common immunologic defect in common variable immunodeficiency is a failure of B-lymphocyte differentiation into plasma cells that produce the various immunoglobulin (Ig) isotypes. Earlier studies suggested a primary B-lymphocyte defect as a cause of common variable immunodeficiency in a small group of patients. B lymphocytes from these patients failed to differentiate into Ig-producing cells when stimulated with pokeweed mitogen (PWM) in vitro, even when cocultured with normal T cells; they were also L-selectin negative. These studies described failure of B-cell differentiation because of altered B-cell surface–molecule expression.
Primary B-cell dysfunction secondary to newly discovered genetic defects has been described in a small number of patients with common variable immunodeficiency (see Causes). These include CD19 deficiency and mutations in the genes that encode TACI (the transmembrane activator and calcium-modulating cyclophilin ligand interactor, TNFRSF13B), ICOS (the inducible costimulator of activated T cells), and BAFFR (the B-cell activating factor of the tumor necrosis factor [TNF] family receptor, TNFRSF13C). CD19 plays a crucial role in regulating B-cell responses to antigens and B-cell survival.
TACI is one of the TNF receptor superfamily members. TACI plays an indispensable role in isotype switching, terminal differentiation of B cells, and T-cell–independent antibody responses. TACI mutations that lead to immunodeficiency account for an estimated 10-15% of patients with common variable immunodeficiency. ICOS mutation is associated with absent ICOS expression on the surface of activated T cells and results in reduced class-switched memory B cells. The BAFFR defect is also associated with reduced class-switched and nonswitched memory B cells.
B cells develop in bone marrow from pluripotent hemopoietic stem cells through rearrangement of immunoglobulin heavy-chain and light-chain genes and initial positive and negative selection in the bone marrow. Mature B cells expressing both IgM and IgD leave bone marrow and enter secondary lymphoid organs. Within the secondary lymphoid follicles, affinity maturation and class switching take place through somatic hypermutation of the variable region genes and class-switch recombination. These B cells become either memory B cells or long-lived plasma cells that home back to the bone marrow and produce high-affinity antibodies.
Enumeration of the B-cell subsets in peripheral blood may be useful in classifying of common variable immunodeficiency. These subsets include class-switched memory B cells (CD27+IgD-IgM-), nonswitched memory B cells (CD27+IgD+IgM+), IgM memory B cells (CD27+IgM+IgDdim), transitional B cells (CD38+++IgM+++), plasmablasts (CD38+++IgM-), mature B cells (CD19+CD21+), and CD21lo B cells (CD19+CD21lo). Expansion of CD21lo B cells in the peripheral blood of patients with common variable immunodeficiency was reported; these were associated with deficiency in activating the calcium pathway.
Several groups have reported classification of common variable immunodeficiency based on B-cell subtype using flow-cytometry techniques. Paris and Freiburg classifications are based on the presence or absence of class-switched memory B cells. A EUROclass trial unified the 2 classifications and attempted to provide clinical links with B-cell subset phenotypes and clinical manifestations. The data included 303 patients with common variable immunodeficiency and suggested that severe reduction in the number of class-switched memory B cells is associated with granulomatous disease, splenomegaly, and autoimmune cytopenias.
Mutations interfering with the regulation of the Ig gene expression, deficiency of memory B cells, and somatic hypermutation (SHM) abnormalities have been reported in patients with common variable immunodeficiency. Memory B cells develop in the germinal centers where SHMs are introduced, followed by antigen-mediated selection of cells with high affinity for the antigen. Low level of SHM, which correlated with increased frequency of severe respiratory tract infection, has been reported in patients with common variable immunodeficiency. B cells from these patients were unable to undergo isotype switching and were unable to upregulate activation markers on B cells when stimulated in vitro.
Other defects described in common variable immunodeficiency include the following:
Lack of protein kinase C activation following stimulation with phorbol ester or anti-µ antibody
Increased spontaneous apoptosis associated with increased expression of CD95 (APO-1/Fas)
Impaired B-cell signal transduction cascade associated with abnormalities in protein tyrosine phosphorylation
Chromosomal radiosensitivity, presumably due to impaired ability to repair DNA
Impaired TLR9 signaling in B cells and plasmacytoid dendritic cells (PDCs), leading to lower expression of costimulatory molecules and reduced production of proinflammatory cytokines
Impaired TLR 7/8 signaling in B cells
Reduced or absent plasma cells in bone marrow was associated with increased complications and adverse clinical outcomes
An overwhelming body of literature suggests that most patients with common variable immunodeficiency have intact B lymphocytes of immature phenotype. Common variable immunodeficiency B cells can secrete immunoglobulins (Ig), although often limited to IgM, if given the appropriate in vitro stimulation. Ig secretion has been induced from common variable immunodeficiency B cells using B-cell mitogens with soluble T-cell factors, monoclonal B-cell differentiation factors, Epstein-Barr virus (EBV), anti-CD40 plus interleukin (IL)-4 and IL-10. CD40 ligand (CD154) is expressed by activated CD4+ cells and is pivotal in inducing B-cell proliferation and differentiation.
Approximately 40% of patients with common variable immunodeficiency have low expression of CD40 ligand on activated T cells. At least 30% of patients with common variable immunodeficiency have lymphopenia due to the low number of CD4+ subsets. These patients also have decreased in vitro production of IL-2 when their peripheral blood mononuclear cells are stimulated in vitro. Decreased IL-2 production with stimuli via T-cell receptors is correlated with diminished CD40 ligand expression. Reduced expression of ICOS was reported in some families with autosomal recessive common variable immunodeficiency due to homozygous mutations in the ICOS gene. ICOS deficiency results in severe B-cell defect, which is caused by impaired T-cell help.
T cells in patients with common variable immunodeficiency have low frequency of antigen-specific precursor T cells following immunization with the neoantigens keyhole-limpet hemocyanin and dinitrophenol (DNP)-Ficoll. Many patients with common variable immunodeficiency have a defect in CD4+ T-cell priming to antigens, as measured by the number of circulating responsive CD4+ T cells following immunization. Many patients have a reduction in CD4+ CD45RA+ ("unprimed") T cells, suggesting activation of T cells.
Most patients with common variable immunodeficiency reportedly have increased production of interferon gamma by circulating CD8+ subsets, increased numbers of DR+/CD4+ T cells with up-regulated Fas expression, and an increased apoptosis. The abnormality appears to reside in CD4+ T cells and can be overcome by stimulating T cells with phorbol myristate acetate (PMA) and ionomycin, an alternative T-cell activation pathway. This is consistent with defective signal transduction in T cells.
Increased endogenous cyclic adenosine monophosphate (cAMP) levels in T cells from patients with common variable immunodeficiency are associated with increased activation of protein kinase A type I (PKAI) in T cells and with decreased proliferative response to anti-CD3. A selective antagonist of PKAI induces a significant increase in anti-CD3-stimulated proliferative responses, particularly in CD4+ lymphocytes. Approximately 25-30% of patients with common variable immunodeficiency have increased numbers of CD8+ lymphocytes, normal or decreased CD4+, and reduced CD4/CD8 ratios (< 1). This increase in CD8+ T cells has been observed most often in patients with splenomegaly and bronchiectasis. These cells coexpress human leukocyte antigen (HLA)-DR and IL-2 receptors, suggesting in vivo activation.
Approximately 60% of patients with common variable immunodeficiency have diminished proliferative responses to T-cell receptor stimuli and decreased induction of gene expression for IL-2, IL-4, IL-5, and interferon gamma. T-cell receptors of patients with common variable immunodeficiency have no evident abnormality; T-cell receptor gene analyses indicate normal heterogeneity of gene rearrangements. TNF production from T cells and monocytes is increased in a subgroup of patients with granulomatous diseases. Standard tests to assess T-cell function, including in vitro proliferation in response to mitogens, antigens, and allogeneic cells, are subnormal in as many as 50% of patients with common variable immunodeficiency with a small subgroup of patients having very low responses. These results support the hypothesis that most patients with common variable immunodeficiency have antibody deficiency secondary to abnormalities in T-cell signaling and defective T-cell and B-cell interactions.
The recovery of Ig production (mostly IgG and IgM) transiently or permanently following human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection has been reported in patients with common variable immunodeficiency. These cases indicate that common variable immunodeficiency is associated with potentially reversible defects in immunoregulatory factors and intact B-cell systems.
A decrease in the number of peripheral blood dendritic cells (DCs) was noted in patients with common variable immunodeficiency. Low numbers of DCs correlated with a greater incidence of autoimmunity, splenomegaly, and granulomatous disease and a higher incidence of clinical complications. DCs play a role in B-cell growth and differentiation of plasma cells into immunoglobulin-secreting plasma cells. Others reported defective functions of DCs in patients with common variable immunodeficiency, inducing weak proliferation of allogeneic T cells and producing significantly low amounts of interleukin 12 upon CD40 signaling.
Increased functional capacity in both classic and alternative complement pathways in patients with common variable immunodeficiency was noted. Many patients with common variable immunodeficiency with increased levels of complement split products, presumably from complement activation, had autoimmune manifestations. Others reported a strong inverse correlation between mannose-binding lectin levels and the frequency of lower respiratory tract infection and bronchiectasis in patients with common variable immunodeficiency.
Other defects include the following:
Reduction in regulatory T cells (T regs) that is associated with autoimmune manifestation, granulomatous disease, and splenomegaly (Reduced T regs correlated significantly with the expansion of CD21 low B cells.)
Reduced expression of markers of T regs, such as FoxP3, granzyme A, and pStat5 that correlated with the degree of T regs dysfunction
Reduced thymic and bone marrow output, reduced TREC(+) and KREC(+) lymphocytes
Lymphopenia and poor lymphocyte proliferation
Increased CD8+ cell numbers
Lack of antigen-specific T cells
Restricted T-cell receptor repertoire
Oligoclonal expansion of CD8+ T cells
Decreased CD4+ CD45RA+ T cells
Decreased production of IL-2, IFN-gamma, IL-4, IL-5, IL-10, and IL-12
Impaired T-cell activation
Impaired intracellular tyrosine kinase expression
Reduced Zap-70 mobilization
Deficient CD28 co-signaling
Accelerated T-cell death and increased expression of CD95
Monocytoid and plasmacytoid dendritic cell defects
Estimated incidence of common variable immunodeficiency is approximately 1 case per 30,000 population based on data over the last 2 decades.
European Society for Immunodificiencies (ESID) Registry reported 2,880 in the internet-based database in 2011. Prevalence (per 100,000 inhabitants) varies greatly by countries (France 0.977. Spain .567, Netherlands 0.865, United Kingdom 0.604, Italy 0.719, Germany 0.524, Poland 0.073).
The prognosis for patients with common variable immunodeficiency is reasonably good if they do not have bronchiectasis and chronic lung damage, severe autoimmune disease, or malignancy.
Resnick et al summarized morbidity and mortality among 473 patients with common variable immunodeficiency at Mt. Sinai Hospital, NY over the past 4 decades. Reduced survival was associated with age at diagnosis, lower baseline IgG, higher IgM, and fewer peripheral B cells. The risk of death was 11 times higher for patients with noninfectious complications. Mortality was associated with lymphoma, any form of hepatitis, functional or structural lung impairment, and GI disease, but not with bronchiectasis, autoimmunity, other cancers, or granulomatous disease.
Chapel et al reported European common variable immunodeficiency registry data that included 326 patients followed for at least 10 years since onset of symptoms. The 75th percentile for survival was 25 years after diagnosis, and the 60th percentile for survival was 41 years after diagnosis. No associations between survival and sex or initial serum IgG, IgA, or IgM levels were noted. In the European registry, the highest mortality rates were in patients with the enteropathy phenotype or the polyclonal lymphocytic infiltrative phenotype. An association between increased mortality and lymphoid malignancy was also noted.
Common variable immunodeficiency has been reported in many different races.
Common variable immunodeficiency equally affects males and females.
This is most frequently diagnosed in adults aged 20-40 years. However, about 28% of subjects are given a diagnosis before age of 21 years. Median age at characteristic symptom onset was 24 years for males and 27 years for females, but males were diagnosed with common variable immunodeficiency earlier at a median age of 30 years than females at a median age of 33.5 years.
[Guideline] Piqueras B, Lavenu-Bombled C, Galicier L, et al. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. J Clin Immunol. 2003 Sep. 23(5):385-400. [Medline].
[Guideline] Warnatz K, Denz A, Drager R, et al. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood. 2002 Mar 1. 99(5):1544-51. [Medline].
Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008 Jan 1. 111(1):77-85. [Medline].
Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012 Feb 16. 119(7):1650-7. [Medline].
Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol. 2009 Jun. 145(6):709-27. [Medline]. [Full Text].
Olerup O, Smith CI, Bjorkander J, Hammarstrom L. Shared HLA class II-associated genetic susceptibility and resistance, related to the HLA-DQB1 gene, in IgA deficiency and common variable immunodeficiency. Proc Natl Acad Sci U S A. 1992 Nov 15. 89(22):10653-7. [Medline].
Bates CA, Ellison MC, Lynch DA, et al. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol. 2004 Aug. 114(2):415-21. [Medline].
Al Kindi M, Mundy J, Sullivan T, Smith W, Kette F, Smith A. Utility of peripheral blood B cell subsets analysis in common variable immunodeficiency. Clin Exp Immunol. 2012 Feb. 167(2):275-81. [Medline].
Ballow M. Clinical and investigational considerations for the use of IGIV therapy. Am J Health Syst Pharm. 2005 Aug 15. 62(16 Suppl 3):S12-8; quiz S19-21. [Medline].
Carsetti R, Rosado MM, Donnanno S, et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol. 2005 Feb. 115(2):412-7. [Medline].
Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005 Aug. 37(8):829-34. [Medline].
Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008 Jul 15. 112(2):277-86. [Medline].
Conley ME, Park CL, Douglas SD. Childhood common variable immunodeficiency with autoimmune disease. J Pediatr. 1986 Jun. 108(6):915-22. [Medline].
Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol. 2008 May. 28 Suppl 1:S42-5. [Medline].
Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999 Jul. 92(1):34-48. [Medline].
Cunningham-Rundles C, Kazbay K, Hassett J, Zhou Z, Mayer L. Brief report: enhanced humoral immunity in common variable immunodeficiency after long-term treatment with polyethylene glycol-conjugated interleukin-2. N Engl J Med. 1994 Oct 6. 331(14):918-21. [Medline].
Durandy A, Wahn V, Petteway S, Gelfand EW. Immunoglobulin replacement therapy in primary antibody deficiency diseases--maximizing success. Int Arch Allergy Immunol. 2005 Mar. 136(3):217-29. [Medline].
Eijkhout HW, van Der Meer JW, Kallenberg CG, at el. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001 Aug 7. 135(3):165-74. [Medline].
Elenitoba-Johnson KS, Jaffe ES. Lymphoproliferative disorders associated with congenital immunodeficiencies. Semin Diagn Pathol. 1997 Feb. 14(1):35-47. [Medline].
Fevang B, Mollnes TE, Holm AM, et al. Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. Clin Exp Immunol. 2005 Dec. 142(3):576-84. [Medline].
Fuss IJ, Friend J, Yang Z, He JP, Hooda L, Boyer J, et al. Nodular Regenerative Hyperplasia in Common Variable Immunodeficiency. J Clin Immunol. 2013 Feb 19. [Medline].
Gathmann B, Binder N, Ehl S, and Kindle G. for ESID Registry Working Party. The European internet-based patient and research database for primary immunodeficiencies: update 2011. Clin Exp Immunol. 2011. 167:479-91.
Giannouli S, Anagnostou D, Soliotis F. Autoimmune manifestations in common variable immunodeficiency. Clin Rheumatol. 2004 Oct. 23(5):449-52. [Medline].
Heeney MM, Zimmerman SA, Ware RE. Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr. 2003 Nov. 143(5):662-5. [Medline].
IUIS Scientific Group. Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies. Clin Exp Immunol. 1999 Oct. 118 Suppl 1:1-28. [Medline].
Johnson ML, Keeton LG, Zhu ZB, Volanakis JE, Cooper MD, Schroeder HW Jr. Age-related changes in serum immunoglobulins in patients with familial IgA deficiency and common variable immunodeficiency (CVID). Clin Exp Immunol. 1997 Jun. 108(3):477-83. [Medline].
Kainulainen L, Varpula M, Liippo K, et al. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 1999 Nov. 104(5):1031-6. [Medline].
Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006 Feb. 5(2):156-9. [Medline].
Lin JH, Liebhaber M, Roberts RL, et al. Etanercept treatment of cutaneous granulomas in common variable immunodeficiency. J Allergy Clin Immunol. 2006 Apr. 117(4):878-82. [Medline].
Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet. 2008 Aug 9. 372(9637):489-502. [Medline].
Quinti I, Soresina A, Agostini C, Spadaro G, Matucci A, Sfika I, et al. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration. J Clin Immunol. 2008 May. 28(3):263-7. [Medline].
Roifman CM, Schroeder H, Berger M, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol. 2003 Sep. 3(9):1325-33. [Medline].
Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies. N Engl J Med. 1995 Aug 17. 333(7):431-40. [Medline].
Salzer U, Grimbacher B. TACItly changing tunes: farewell to a yin and yang of BAFF receptor and TACI in humoral immunity? New genetic defects in common variable immunodeficiency. Curr Opin Allergy Clin Immunol. 2005 Dec. 5(6):496-503. [Medline].
Schaffer AA, Pfannstiel J, Webster AD, et al. Analysis of families with common variable immunodeficiency (CVID) and IgA deficiency suggests linkage of CVID to chromosome 16q. Hum Genet. 2006 Feb. 118(6):725-9. [Medline].
Schejbel L, Marquart H, Andersen V, et al. Deficiency of somatic hypermutation of immunoglobulin G transcripts is a better predictor of severe respiratory tract infections than lack of memory B cells in common variable immunodeficiency. J Clin Immunol. 2005 Jul. 25(4):392-403. [Medline].
Spickett GP, Webster ADB, Farrant J. Cellular abnormalities in common variable immunodeficiency. In: Rosen FS, Seligmann M, eds. Immunodeficiencies. Philadelphia: Harwood Academie. 1993:111-26.
Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J. 1997 Jul. 16(7):696-707. [Medline].
Stiehm ER, Casillas AM, Finkelstein JZ, et al. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol. 1998 Jun. 101(6 Pt 1):848-9. [Medline].
Stray-Pedersen A, Abrahamsen TG, Froland SS. Primary immunodeficiency diseases in Norway. J Clin Immunol. 2000 Nov. 20(6):477-85. [Medline].
Taubenheim N, von Hornung M, Durandy A, et al. Defined blocks in terminal plasma cell differentiation of common variable immunodeficiency patients. J Immunol. 2005 Oct 15. 175(8):5498-503. [Medline].
Thiel J, Kimmig L, Salzer U, Grudzien M, Lebrecht D, Hagena T. Genetic CD21 deficiency is associated with hypogammaglobulinemia. J Allergy Clin Immunol. 2012 Mar. 129(3):801-810.e6. [Medline].
van de Ven AA, Compeer EB, Bloem AC, van de Corput L, van Gijn M, van Montfrans JM. Defective calcium signaling and disrupted CD20-B-cell receptor dissociation in patients with common variable immunodeficiency disorders. J Allergy Clin Immunol. 2012 Mar. 129(3):755-761.e7. [Medline].
Viallard JF, Camou F, Andre M, et al. Altered dendritic cell distribution in patients with common variable immunodeficiency. Arthritis Res Ther. 2005. 7(5):R1052-5. [Medline].
Vorechovsky I, Zetterquist H, Paganelli R, et al. Family and linkage study of selective IgA deficiency and common variable immunodeficiency. Clin Immunol Immunopathol. 1995 Nov. 77(2):185-92. [Medline].
Watts WJ, Watts MB, Dai W, et al. Respiratory dysfunction in patients with common variable hypogammaglobulinemia. Am Rev Respir Dis. 1986 Oct. 134(4):699-703. [Medline].
Wright JJ, Birx DL, Wagner DK, et al. Normalization of antibody responsiveness in a patient with common variable hypogammaglobulinemia and HIV infection. N Engl J Med. 1987 Dec 10. 317(24):1516-20. [Medline].
Zhang L, Radigan L, Salzer U, et al. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J Allergy Clin Immunol. 2007 Nov. 120(5):1178-85. [Medline].
|Genetic defect||Chromosomal location||Inheritance||Phenotype||B cells|
|TNFRSF13B (TACI); approximately 10% of cases||17p11.2||Autosomal dominant (AD)||Common variable immunodeficiency, selective immunoglobulin A deficiency (SIgAD)||< 5% of cases involve absent TACI expression; 95% of cases have normal TACI expression on B cells; low-to-absent IgA levels; autoimmune disease; lymphoproliferative disease; splenomegaly; reduced class-switched memory B cells|
|TNFRSF13C (BAFF-R); < 1% of cases||22q13.2||Autosomal recessive (AR)||Late-onset, incomplete penetrance||Absent BAFF-R on B-cell surface; reduced class-switched and non–class-switched memory B cells; increased transitional B cells; impaired response to polysaccharide antigen|
|ICOS; approximately 2% of cases||2q33||AR||Early and late onset||Absent ICOS on activated T cells; reduced class-switched memory B cells; nodular lymphoid hyperplasia; autoimmunity; predisposition to neoplasm|
|CD19; < 1% of cases||16p11.2||AR||Early and late onset||Low-to-absent CD19 on B cells; reduced class-switched memory B cells; low CD21+ expression on B cells; normal number of CD20+ cells in peripheral blood|
|CD81; < 1% of cases||AR||Unclear||Impaired Ca++ flux after BCR stimulation; autoimmunity; impaired response to protein and polysaccharide antigens; nearly absent CD19 expression|
|CD20; < 1% of cases||AR||Unclear||Reduced switched memory B cells; impaired somatic hypermutation; impaired response to pneumococcal polysaccharide antigens|
|CD21; < 1% of cases||AR||Unclear||Reduced class-switched memory B cells; hypogammaglobulinemia; reduced binding of C3d-containing immune complexes and EBV-gp350 to B cells; impaired response to pneumococcal polysaccharide antigens|
|Brand (Manufacturer)||Virus Inactivation process||pH/ Additives *||Osmolality (mOsm/kg)||Parenteral Form & Final Concentrations||IgA Content mcg/mL||Route of administration|
|Fractionation and depth filtration, pH 4 and pepsin treatment, nanofiltration||6.4-6.8; Sucrose||In normal saline: 498-1074; in 5% dextrose: 444-1020; in sterile water: 192-768||Lyophilized powder 3%, 6%, 9%, 12%||720||IV|
|PEG precipitation, ion-exchange chromatography, low pH treatment, solvent detergent treatment, nanofiltration||5.1-6; Sorbitol||240-370||Liquid 5%, 10%||< 50||IV|
|Solvent detergent (S/D) treatment, nanofiltration, low pH incubation at elevated temp||4.6-5.1; Glycine||240-300||Liquid 10%, for IV and subcutaneous administration||37||IV or subcutaneous|
|Ultrafiltration, ion exchange chromatography, solvent detergent (S/D) treatment||6.4-7.2;
|5%: 636; 10%:1250||Lyophilized powder
|< 2.2 (5% solution)||IV|
|Caprylate-chromatography purification, cloth and depth filtration,
pH 4 incubation
|4-4.5; Glycine||258||Liquid 10%||46||IV or Subcutaneous|
|Solvent/detergent treatment targeted to enveloped viruses; virus filtration using Pall Ultipor to remove small viruses including nonenveloped viruses; low pH incubation||4.8-5.1; Contains sorbitol (40 mg/mL); do not administer if fructose intolerant||420-500||Ready-for-use liquid 5%||< 10||IV|
|Vivaglobin(CSL Behring)||Cold alcohol fractionation, enzymatically degraded.||6.4-7.2||Liquid 16%||< 1.7||Subcutaneous|
|pH 4 incubation, nanofiltration, depth filtration||4.6-5.2
|240-440||Liquid 10%||< 25||IV|
|Cold alcohol freactionation, octanoic acid fractionation, and anion exchange chromatography||4.6-5.2
|Liquid 20%||< 50||Subcutaneous|